TAPBP and neoplasm: The absence of tapasin hampers the antigen processing of tumor-associated antigens and leads to evasion of tumor-associated antigen–specific CTLs recognition, leading to poorer prognosis (such as colorectal cancer, glioblastoma, and NSCLC), tumor progression and metastasis, and lower CD8+T tumor-infiltrating lymphocytes (42, 43, 44, 45, 46).